{"id":"bmn-111","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BMN 111 mimics the action of C-type natriuretic peptide, a naturally occurring hormone that signals through NPR-B receptors in the growth plate cartilage. By activating this pathway, the drug stimulates endochondral ossification and longitudinal bone growth, thereby increasing adult height. This mechanism addresses the underlying pathophysiology of skeletal dysplasias characterized by impaired bone growth.","oneSentence":"BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:34.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Achondroplasia (to increase adult height)"},{"name":"Other skeletal dysplasias (under investigation)"}]},"trialDetails":[{"nctId":"NCT04219007","phase":"PHASE2","title":"Vosoritide for Selected Genetic Causes of Short Stature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew Dauber","startDate":"2020-08-04","conditions":"Short Stature","enrollment":56},{"nctId":"NCT04554940","phase":"PHASE2","title":"A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2020-10-10","conditions":"Achondroplasia","enrollment":20},{"nctId":"NCT03424018","phase":"PHASE3","title":"An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2017-12-12","conditions":"Achondroplasia","enrollment":119},{"nctId":"NCT03989947","phase":"PHASE2","title":"An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2019-06-12","conditions":"Achondroplasia","enrollment":73},{"nctId":"NCT02724228","phase":"PHASE2","title":"A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2016-01-26","conditions":"Achondroplasia","enrollment":30},{"nctId":"NCT03583697","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2018-06-13","conditions":"Achondroplasia","enrollment":75},{"nctId":"NCT05813314","phase":"PHASE1","title":"Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants","status":"TERMINATED","sponsor":"BioMarin Pharmaceutical","startDate":"2023-03-15","conditions":"Achondroplasia","enrollment":36},{"nctId":"NCT03197766","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2016-12-12","conditions":"Achondroplasia","enrollment":121},{"nctId":"NCT02055157","phase":"PHASE2","title":"A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2014-01-13","conditions":"Achondroplasia","enrollment":35},{"nctId":"NCT01590446","phase":"PHASE1","title":"A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2012-02","conditions":"Achondroplasia","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Modified recombinant human C-type natriuretic peptide","Vosoritide","Modified C-Natriuretic Peptide, ProCNP38"],"phase":"phase_3","status":"active","brandName":"BMN 111","genericName":"BMN 111","companyName":"BioMarin Pharmaceutical","companyId":"biomarin-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height. Used for Achondroplasia (to increase adult height), Other skeletal dysplasias (under investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}